iaso biotherapeutics usa limited

2 articles with iaso biotherapeutics usa limited

• IASO Biotheraputics' CT120 Granted Orphan Drug Designation by the U.S. FDA

  11/26/2021

  IASO Biotherapeutics announced on Oct 26, 2021 that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted the Orphan Drug Designation to the company's in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor -T cell therapy for the treatment of acute lymphoblastic leukemia.

• IASO Bio Appoints Industry Veteran Dr. Alan Fu Chief Financial Officer

  10/19/2021

  IASO Biotherapeutics has appointed Dr. Alan Fu as Chief Financial Officer (CFO), reporting to Maxwell Wang, CEO, IASO Bio.